Gopichand Pendurti is an Oncology physician. OpenAlex indexes 15 publications with 412 citations (h-index 6).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
902 N Riverside Rd
Ste 200
Saint Joseph, MO 645072518
Telephone
816-271-1301Registry record last updated 8 May 2017.
Industry payments
54 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Biotech, Inc.Program year20257 payments
- E.R. Squibb & Sons, L.L.C.Program year20259 payments
- Celgene CorporationProgram year20258 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Blood & clotting
91%Iron, parenteral preparations90.7%Ferric carboxymaltose90%Ferric derisomaltose10%Part B, office-administered≥16 patientsFactor Xa inhibitor0.3%Eliquis60%Xarelto40%Part D<11 patientsSensory organs
7.2%Corticosteroid7.2%Dexamethasone sodium phosphate98%Dexamethasone2%Part D + Part B≥20 patientsMetabolism & gastrointestinal
0.5%Serotonin-3 Receptor Antagonist0.2%Ondansetron Odt68%Ondansetron Hcl32%Part D<11 patientsCorticosteroid0.2%Prednisone100%Part D≥15 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- IL1RAP potentiates multiple oncogenic signaling pathways in AML
The Journal of Experimental Medicine
2018 - Survival outcome and prognostic model of patients with colorectal cancer on phase 1 trials
Investigational New Drugs
2018 - Targeting the anterior superior iliac spine yields significantly longer bone marrow cores
Journal of Clinical Pathology
2017
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”